160 related articles for article (PubMed ID: 31506386)
1. NKG2D Controls Natural Reactivity of Vγ9Vδ2 T Lymphocytes against Mesenchymal Glioblastoma Cells.
Chauvin C; Joalland N; Perroteau J; Jarry U; Lafrance L; Willem C; Retière C; Oliver L; Gratas C; Gautreau-Rolland L; Saulquin X; Vallette FM; Vié H; Scotet E; Pecqueur C
Clin Cancer Res; 2019 Dec; 25(23):7218-7228. PubMed ID: 31506386
[TBL] [Abstract][Full Text] [Related]
2. IL-21 Increases the Reactivity of Allogeneic Human Vγ9Vδ2 T Cells Against Primary Glioblastoma Tumors.
Joalland N; Chauvin C; Oliver L; Vallette FM; Pecqueur C; Jarry U; Scotet E
J Immunother; 2018 Jun; 41(5):224-231. PubMed ID: 29683891
[TBL] [Abstract][Full Text] [Related]
3. Repeated systemic administrations of both aminobisphosphonates and human Vγ9Vδ2 T cells efficiently control tumor development in vivo.
Santolaria T; Robard M; Léger A; Catros V; Bonneville M; Scotet E
J Immunol; 2013 Aug; 191(4):1993-2000. PubMed ID: 23836057
[TBL] [Abstract][Full Text] [Related]
4. Vgamma9Vdelta2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas.
Bouet-Toussaint F; Cabillic F; Toutirais O; Le Gallo M; Thomas de la Pintière C; Daniel P; Genetet N; Meunier B; Dupont-Bierre E; Boudjema K; Catros V
Cancer Immunol Immunother; 2008 Apr; 57(4):531-9. PubMed ID: 17764010
[TBL] [Abstract][Full Text] [Related]
5. Phosphostim-activated gamma delta T cells kill autologous metastatic renal cell carcinoma.
Viey E; Fromont G; Escudier B; Morel Y; Da Rocha S; Chouaib S; Caignard A
J Immunol; 2005 Feb; 174(3):1338-47. PubMed ID: 15661891
[TBL] [Abstract][Full Text] [Related]
6. V gamma 9V delta 2 T cell response to colon carcinoma cells.
Corvaisier M; Moreau-Aubry A; Diez E; Bennouna J; Mosnier JF; Scotet E; Bonneville M; Jotereau F
J Immunol; 2005 Oct; 175(8):5481-8. PubMed ID: 16210656
[TBL] [Abstract][Full Text] [Related]
7. Preferential Infiltration of Unique Vγ9Jγ2-Vδ2 T Cells Into Glioblastoma Multiforme.
Lee M; Park C; Woo J; Kim J; Kho I; Nam DH; Park WY; Kim YS; Kong DS; Lee HW; Kim TJ
Front Immunol; 2019; 10():555. PubMed ID: 30967876
[TBL] [Abstract][Full Text] [Related]
8. Stereotaxic administrations of allogeneic human Vγ9Vδ2 T cells efficiently control the development of human glioblastoma brain tumors.
Jarry U; Chauvin C; Joalland N; Léger A; Minault S; Robard M; Bonneville M; Oliver L; Vallette FM; Vié H; Pecqueur C; Scotet E
Oncoimmunology; 2016 Jun; 5(6):e1168554. PubMed ID: 27471644
[TBL] [Abstract][Full Text] [Related]
9. Low-Density Lipoprotein Uptake Inhibits the Activation and Antitumor Functions of Human Vγ9Vδ2 T Cells.
Rodrigues NV; Correia DV; Mensurado S; Nóbrega-Pereira S; deBarros A; Kyle-Cezar F; Tutt A; Hayday AC; Norell H; Silva-Santos B; Dias S
Cancer Immunol Res; 2018 Apr; 6(4):448-457. PubMed ID: 29358174
[TBL] [Abstract][Full Text] [Related]
10. B7H3-targeting chimeric antigen receptor modification enhances antitumor effect of Vγ9Vδ2 T cells in glioblastoma.
Wang Y; Ji N; Zhang Y; Chu J; Pan C; Zhang P; Ma W; Zhang X; Xi JJ; Chen M; Zhang Y; Zhang L; Sun T
J Transl Med; 2023 Sep; 21(1):672. PubMed ID: 37770968
[TBL] [Abstract][Full Text] [Related]
11. NKG2D costimulates human V gamma 9V delta 2 T cell antitumor cytotoxicity through protein kinase C theta-dependent modulation of early TCR-induced calcium and transduction signals.
Nedellec S; Sabourin C; Bonneville M; Scotet E
J Immunol; 2010 Jul; 185(1):55-63. PubMed ID: 20511557
[TBL] [Abstract][Full Text] [Related]
12. CD94/NKG2 inhibitory receptor complex modulates both anti-viral and anti-tumoral responses of polyclonal phosphoantigen-reactive V gamma 9V delta 2 T lymphocytes.
Poccia F; Cipriani B; Vendetti S; Colizzi V; Poquet Y; Battistini L; López-Botet M; Fournié JJ; Gougeon ML
J Immunol; 1997 Dec; 159(12):6009-17. PubMed ID: 9550399
[TBL] [Abstract][Full Text] [Related]
13. Role of NKG2D and its ligands in the anti-infectious activity of Vγ9Vδ2 T cells against intracellular bacteria.
Bessoles S; Ni M; Garcia-Jimenez S; Sanchez F; Lafont V
Eur J Immunol; 2011 Jun; 41(6):1619-28. PubMed ID: 21469127
[TBL] [Abstract][Full Text] [Related]
14. In vivo phosphoantigen levels in bisphosphonate-treated human breast tumors trigger Vγ9Vδ2 T-cell antitumor cytotoxicity through ICAM-1 engagement.
Benzaïd I; Mönkkönen H; Bonnelye E; Mönkkönen J; Clézardin P
Clin Cancer Res; 2012 Nov; 18(22):6249-59. PubMed ID: 23032740
[TBL] [Abstract][Full Text] [Related]
15. NK cells with KIR2DS2 immunogenotype have a functional activation advantage to efficiently kill glioblastoma and prolong animal survival.
Gras Navarro A; Kmiecik J; Leiss L; Zelkowski M; Engelsen A; Bruserud Ø; Zimmer J; Enger PØ; Chekenya M
J Immunol; 2014 Dec; 193(12):6192-206. PubMed ID: 25381437
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxic human peripheral blood-derived γδT cells kill glioblastoma cell lines: implications for cell-based immunotherapy for patients with glioblastoma.
Nakazawa T; Nakamura M; Park YS; Motoyama Y; Hironaka Y; Nishimura F; Nakagawa I; Yamada S; Matsuda R; Tamura K; Sugimoto T; Takeshima Y; Marutani A; Tsujimura T; Ouji N; Ouji Y; Yoshikawa M; Nakase H
J Neurooncol; 2014 Jan; 116(1):31-9. PubMed ID: 24062140
[TBL] [Abstract][Full Text] [Related]
17. Characterization and immunotherapeutic potential of gammadelta T-cells in patients with glioblastoma.
Bryant NL; Suarez-Cuervo C; Gillespie GY; Markert JM; Nabors LB; Meleth S; Lopez RD; Lamb LS
Neuro Oncol; 2009 Aug; 11(4):357-67. PubMed ID: 19211933
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy and zoledronate sensitize solid tumour cells to Vgamma9Vdelta2 T cell cytotoxicity.
Mattarollo SR; Kenna T; Nieda M; Nicol AJ
Cancer Immunol Immunother; 2007 Aug; 56(8):1285-97. PubMed ID: 17265022
[TBL] [Abstract][Full Text] [Related]
19. The way of interaction between Vγ9Vδ2 T cells and tumor cells.
Zhang T; Wang J; Zhao A; Xia L; Jin H; Xia S; Shi T
Cytokine; 2023 Feb; 162():156108. PubMed ID: 36527892
[TBL] [Abstract][Full Text] [Related]
20. Production of TNF-alpha by human V gamma 9V delta 2 T cells via engagement of Fc gamma RIIIA, the low affinity type 3 receptor for the Fc portion of IgG, expressed upon TCR activation by nonpeptidic antigen.
Lafont V; Liautard J; Liautard JP; Favero J
J Immunol; 2001 Jun; 166(12):7190-9. PubMed ID: 11390467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
